Josh Resnick
Cidara TherapeuticsAbout Josh Resnick
Josh Resnick, M.D. (age 50) joined Cidara’s Board in January 2025 and serves as an independent Class II director with a term expiring at the 2026 annual meeting. He is a Partner on the Venture Team at RA Capital Management (since 2018), a faculty member at Harvard Medical School, and an attending physician in emergency medicine at Massachusetts General Hospital. He holds an M.D. from the University of Pennsylvania, an MBA from Wharton, and a B.A. in chemistry from Williams College .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| RA Capital Management | Partner, Venture Team | 2018–present | Led investing and company formation across drug development stages |
| SV Health Investors | Co-Lead, U.S. biotech practice | Not disclosed | Responsible for U.S. venture creation; ran incubator Brahma Discovery |
| MRL Ventures Fund (Merck & Co.) | President & Managing Partner | Not disclosed | Led early-stage therapeutics corporate VC |
| Atlas Venture | Venture Partner | Not disclosed | Company formation; seed/Series A investing |
| Prism Venture Partners | Partner | Not disclosed | Company formation; seed/Series A investing |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Harvard Medical School | Faculty | Not disclosed | Academic appointment |
| Massachusetts General Hospital | Attending Physician, Emergency Medicine | Not disclosed | Clinical practice |
| PepGen Inc. | Director | Since Nov 2020 | Public biotech board |
| Sionna Therapeutics, Inc. | Director | Since Dec 2019 | Public biotech board |
| Vor Biopharma Inc. | Director | Since Feb 2019 | Public biotech board |
| Aerovate Therapeutics, Inc. | Director | Since Oct 2018 | Public biotech board |
Board Governance
- Independence: The Board determined all directors other than the CEO (Jeffrey Stein) are independent under Nasdaq rules; Resnick is independent .
- Committee assignments: As of the 2025 proxy, Audit Committee (Burgess—Chair, Schroeder, Mineo), Compensation & Human Capital (Schroeder—Chair, Canale-Theakston, Mineo), Nominating & Governance (Bassler—Chair, Merson, Burgess); Resnick is not listed on any committee and holds no chair roles .
- Attendance and engagement: The Board met six times in 2024; all directors (serving in 2024) attended at least 75% of Board and committee meetings. Independent directors held five executive sessions in 2024. Resnick joined in January 2025, so 2024 attendance does not apply to him .
- Chair/Leadership: Daniel Burgess serves as non-executive Chairman, with separate committee chairs reporting to the Board .
Fixed Compensation
| Component | Amount/Terms |
|---|---|
| Annual Board retainer (cash) | $40,000 per year |
| Chair retainers (if applicable) | Audit Chair $20,000; Compensation Chair $15,000; Nominating Chair $10,000 |
| Committee member retainers | Audit $10,000; Compensation $7,500; Nominating $5,000 |
| Meeting fees | Not disclosed in policy |
Performance Compensation
| Award | Grant size | Vesting | Exercise/Term | Change-in-control | Notes |
|---|---|---|---|---|---|
| Initial stock option (on appointment) | 22,200 shares | 1/3 on 1st anniversary; remaining 2/3 monthly over next 24 months; fully vested at 3 years | Exercise price = FMV at grant; 10-year term; 12-month post-termination exercise (other than death, disability, cause) | Full vesting on change-in-control | Granted January 3, 2025 |
| Annual stock option (at each annual meeting) | 11,100 shares; first grant pro-rated based on days served before 2025 meeting | Vests in full on earlier of 1-year anniversary or day prior to next annual meeting | Exercise price = FMV at grant; 10-year term; 12-month post-termination exercise | Full vesting on change-in-control | Automatic annual grant while serving |
| Plan-level clawback | Awards subject to Company’s incentive compensation recoupment policy | Applies to awards under 2024 plan (amended 2025) |
Other Directorships & Interlocks
- Investor affiliation: Resnick is a Partner at RA Capital Management. RA Capital Healthcare Fund is a 9.99% beneficial owner of Cidara common stock and holds Series A Preferred Stock; RA participated in the November 2024 private placement ($25M) for common stock and pre-funded warrants .
- Appointment disclosure: On appointment, the company disclosed there are no transactions involving Resnick requiring related-party disclosure under Item 404(a) of Regulation S-K; the Company also entered into a standard indemnity agreement with him .
Expertise & Qualifications
- Medical and clinical expertise: Emergency medicine attending physician; faculty role at Harvard Medical School .
- Venture and company-building expertise: Senior roles at RA Capital, SV Health Investors, MRL Ventures (Merck), Atlas Venture, Prism Venture Partners—covering investment, venture creation, and early-stage to commercialization .
- Board experience: Multiple public biotech boards (PepGen, Sionna Therapeutics, Vor Biopharma, Aerovate Therapeutics) .
- Education: M.D. (University of Pennsylvania), MBA (Wharton), B.A. Chemistry (Williams College) .
Equity Ownership
| Holder | Common shares | % Common | Series A Preferred | % Series A | Options exercisable within 60 days | Unvested options |
|---|---|---|---|---|---|---|
| Josh Resnick, M.D. (as of April 21, 2025) | — | — | — | — | 0 (not listed) | 22,200 initial grant (vesting over 3 years) |
- Hedging/pledging policy: Directors are prohibited from short sales, margin accounts, pledging shares, buying/selling puts or calls, or other hedging transactions in Company securities .
Governance Assessment
- Independence and structure: Resnick is an independent director under Nasdaq rules; separation of Chair and CEO roles supports Board oversight .
- Committee status: Not currently seated on Audit, Compensation, or Nominating committees; this limits committee-level influence but reduces potential conflicts in sensitive areas (e.g., compensation) .
- Compensation alignment: Director pay is a modest cash retainer plus time-vested options with 10-year terms; equity grants vest fully on change-in-control, which is standard but creates acceleration risk if a transaction is imminent .
- Ownership and alignment: As of the 2025 proxy record date, Resnick reported no beneficial ownership; initial option grant is unvested and time-based. Company policy prohibits hedging and pledging, which is positive for alignment .
- Potential conflicts (RED FLAG to monitor): RA Capital’s significant ownership and prior participation in Cidara financings, combined with Resnick’s RA affiliation, warrants ongoing monitoring for conflicts in capital raising, strategic transactions, or governance decisions—though the company disclosed no related-party transactions involving Resnick at appointment and affirmed Board-wide independence (other than CEO) .
- Attendance and engagement: Board met six times in 2024 with ≥75% attendance by then-serving directors; independent directors held five executive sessions. Resnick’s tenure began in 2025, so no 2024 attendance data apply .